The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

Raymond U. Osarogiagbon; Ramon Rami-Porta; Ming Sound Tsao; Luis M. Montuenga; Katherine K. Nishimura; Dorothy J. Giroux; William Travis; Hisao Asamura; Valerie Rusch; David P. Carbone; Fred R. Hirsch

doi:10.1016/j.jtho.2021.03.003

The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities

Raymond U. Osarogiagbon, Ramon Rami-Porta, Ming Sound Tsao, Luis M. Montuenga, Katherine K. Nishimura, Dorothy J. Giroux, William Travis, Hisao Asamura, Valerie Rusch, David P. Carbone, Fred R. Hirsch

外科学(呼吸器)

研究成果: Editorial › 査読

9 被引用数 (Scopus)

本文言語	English
ページ（範囲）	897-901
ページ数	5
ジャーナル	Journal of Thoracic Oncology
巻	16
号	6
DOI	https://doi.org/10.1016/j.jtho.2021.03.003
出版ステータス	Published - 2021 6月

ASJC Scopus subject areas

腫瘍学
呼吸器内科

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.jtho.2021.03.003

他のファイルとリンク

引用スタイル

Osarogiagbon, R. U., Rami-Porta, R., Tsao, M. S., Montuenga, L. M., Nishimura, K. K., Giroux, D. J., Travis, W., Asamura, H., Rusch, V., Carbone, D. P., & Hirsch, F. R. (2021). The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. Journal of Thoracic Oncology, 16(6), 897-901. https://doi.org/10.1016/j.jtho.2021.03.003

Osarogiagbon, RU, Rami-Porta, R, Tsao, MS, Montuenga, LM, Nishimura, KK, Giroux, DJ, Travis, W, Asamura, H, Rusch, V, Carbone, DP & Hirsch, FR 2021, 'The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities', Journal of Thoracic Oncology, vol. 16, no. 6, pp. 897-901. https://doi.org/10.1016/j.jtho.2021.03.003

@article{89c6895b285b4e20b3fefb85ad415e53,

title = "The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities",

author = "Osarogiagbon, {Raymond U.} and Ramon Rami-Porta and Tsao, {Ming Sound} and Montuenga, {Luis M.} and Nishimura, {Katherine K.} and Giroux, {Dorothy J.} and William Travis and Hisao Asamura and Valerie Rusch and Carbone, {David P.} and Hirsch, {Fred R.}",

note = "Funding Information: Disclosure: Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; owns stocks in Eli Lilly , Gilead Sciences , and Pfizer ; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, AstraZeneca , Eli Lilly, Triptych Healthcare Partners , and Genentech/Roche ; and is the founder of Oncobox Device, Inc. Dr. Montuenga reports receiving speaker{\textquoteright} bureau and a research grant from AstraZeneca; is a licensed patent co-holder on Complement in Lung Cancer early detection from AMADIX ; and a received a research grant from Bristol-Myers Squibb . Ms. Giroux reports receiving grants from the International Association for the Study of Lung Cancer during the conduct of the study. Dr. Asamura reports receiving personal fees from lecture fees outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc ., Genentech; nonfinancial support from Intuitive Surgical; other fees from the National Institute of Health Coordinating Center for Clinical Trials, and other fees from the MARS 2 Trial Data Safety Monitoring Committee outside the submitted work. Dr. Hirsch reports to have participated in scientific advisory boards for Bristol-Myers Squibb, Merck, AstraZeneca, Novartis , Daiichi , Regeneron/Sanofi , OncoCyte , Amgen , and Genentech/Roche; received research funding (through the University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, and AbbVie; and owns a patent (through University of Colorado) for the work entitled “EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy.” The remaining authors declare no conflict of interest. Funding Information: Disclosure: Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; owns stocks in Eli Lilly, Gilead Sciences, and Pfizer; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, AstraZeneca, Eli Lilly, Triptych Healthcare Partners, and Genentech/Roche; and is the founder of Oncobox Device, Inc. Dr. Montuenga reports receiving speaker{\textquoteright} bureau and a research grant from AstraZeneca; is a licensed patent co-holder on Complement in Lung Cancer early detection from AMADIX; and a received a research grant from Bristol-Myers Squibb. Ms. Giroux reports receiving grants from the International Association for the Study of Lung Cancer during the conduct of the study. Dr. Asamura reports receiving personal fees from lecture fees outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc., Genentech; nonfinancial support from Intuitive Surgical; other fees from the National Institute of Health Coordinating Center for Clinical Trials, and other fees from the MARS 2 Trial Data Safety Monitoring Committee outside the submitted work. Dr. Hirsch reports to have participated in scientific advisory boards for Bristol-Myers Squibb, Merck, AstraZeneca, Novartis, Daiichi, Regeneron/Sanofi, OncoCyte, Amgen, and Genentech/Roche; received research funding (through the University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, and AbbVie; and owns a patent (through University of Colorado) for the work entitled “EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy.” The remaining authors declare no conflict of interest. Funding Information: This study was supported by grants from the National Institute of Health (grant numbers 2UG1CA189873-06, 2R01CA172253, and 1UM1CA233080 through Dr. Osarogiagbon) and the ISCIII-Fondo de Investigaci{\'o}n Sanitaria (grant number PI19/00098 through Dr. Montuenga). This work was funded by the IASLC, including with funds obtained through unrestricted grants from the pharmaceutical industry. ",

year = "2021",

month = jun,

doi = "10.1016/j.jtho.2021.03.003",

language = "English",

volume = "16",

pages = "897--901",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "6",

}

TY - JOUR

T1 - The International Association for the Study of Lung Cancer Molecular Database Project

T2 - Objectives, Challenges, and Opportunities

AU - Osarogiagbon, Raymond U.

AU - Rami-Porta, Ramon

AU - Tsao, Ming Sound

AU - Montuenga, Luis M.

AU - Nishimura, Katherine K.

AU - Giroux, Dorothy J.

AU - Travis, William

AU - Asamura, Hisao

AU - Rusch, Valerie

AU - Carbone, David P.

AU - Hirsch, Fred R.

N1 - Funding Information: Disclosure: Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; owns stocks in Eli Lilly , Gilead Sciences , and Pfizer ; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, AstraZeneca , Eli Lilly, Triptych Healthcare Partners , and Genentech/Roche ; and is the founder of Oncobox Device, Inc. Dr. Montuenga reports receiving speaker’ bureau and a research grant from AstraZeneca; is a licensed patent co-holder on Complement in Lung Cancer early detection from AMADIX ; and a received a research grant from Bristol-Myers Squibb . Ms. Giroux reports receiving grants from the International Association for the Study of Lung Cancer during the conduct of the study. Dr. Asamura reports receiving personal fees from lecture fees outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc ., Genentech; nonfinancial support from Intuitive Surgical; other fees from the National Institute of Health Coordinating Center for Clinical Trials, and other fees from the MARS 2 Trial Data Safety Monitoring Committee outside the submitted work. Dr. Hirsch reports to have participated in scientific advisory boards for Bristol-Myers Squibb, Merck, AstraZeneca, Novartis , Daiichi , Regeneron/Sanofi , OncoCyte , Amgen , and Genentech/Roche; received research funding (through the University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, and AbbVie; and owns a patent (through University of Colorado) for the work entitled “EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy.” The remaining authors declare no conflict of interest. Funding Information: Disclosure: Dr. Osarogiagbon owns patents for a lymph node specimen collection kit; owns stocks in Eli Lilly, Gilead Sciences, and Pfizer; has worked as a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, AstraZeneca, Eli Lilly, Triptych Healthcare Partners, and Genentech/Roche; and is the founder of Oncobox Device, Inc. Dr. Montuenga reports receiving speaker’ bureau and a research grant from AstraZeneca; is a licensed patent co-holder on Complement in Lung Cancer early detection from AMADIX; and a received a research grant from Bristol-Myers Squibb. Ms. Giroux reports receiving grants from the International Association for the Study of Lung Cancer during the conduct of the study. Dr. Asamura reports receiving personal fees from lecture fees outside of the submitted work. Dr. Rusch reports receiving grants from Genelux, Inc., Genentech; nonfinancial support from Intuitive Surgical; other fees from the National Institute of Health Coordinating Center for Clinical Trials, and other fees from the MARS 2 Trial Data Safety Monitoring Committee outside the submitted work. Dr. Hirsch reports to have participated in scientific advisory boards for Bristol-Myers Squibb, Merck, AstraZeneca, Novartis, Daiichi, Regeneron/Sanofi, OncoCyte, Amgen, and Genentech/Roche; received research funding (through the University of Colorado) from Amgen, Biodesix, Rain Therapeutics, Mersana, and AbbVie; and owns a patent (through University of Colorado) for the work entitled “EGFR protein and Gene Copy Number as Predictive Biomarkers for EGFR Therapy.” The remaining authors declare no conflict of interest. Funding Information: This study was supported by grants from the National Institute of Health (grant numbers 2UG1CA189873-06, 2R01CA172253, and 1UM1CA233080 through Dr. Osarogiagbon) and the ISCIII-Fondo de Investigación Sanitaria (grant number PI19/00098 through Dr. Montuenga). This work was funded by the IASLC, including with funds obtained through unrestricted grants from the pharmaceutical industry.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85104938883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104938883&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2021.03.003

DO - 10.1016/j.jtho.2021.03.003

M3 - Editorial

C2 - 33771657

AN - SCOPUS:85104938883

SN - 1556-0864

VL - 16

SP - 897

EP - 901

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 6

ER -